Thyroglobulin as a Tumor Marker in Differentiated Thyroid Cancer – Clinical Considerations
作者： Marin Prpić , Maja Franceschi , Matija Romić , Tomislav Jukić , Zvonko Kusić
DOI: 10.20471/ACC.2018.57.03.16
关键词:
摘要: … the degree of response to initial therapy and increasing the risk of adverse effects related to … Immunometric assays are more sensitive than RIA and have shorter incubation time, wider …
irb.hr
sci-hub.se 参考文章(80)
J. A. Krämer, K. W. Schmid, H. Dralle, M. Dietlein, H. Schicha, C. Sauerland, T. Frankewitsch, O. Schober, B. Riemann, , Risk stratification of patients with locally aggressive differentiated thyroid cancer. Results of the MSDS trial. Nuklearmedizin-nuclear Medicine. ,vol. 49, pp. 79- 84 ,(2010) , 10.3413/NUKMED-0302
Aldona Kowalska, Iwona Pałyga, Danuta Gąsior-Perczak, Agnieszka Walczyk, Tomasz Trybek, Anna Słuszniak, Ryszard Mężyk, Stanisław Góźdź, The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer PLOS ONE. ,vol. 10, pp. e0133852- ,(2015) , 10.1371/JOURNAL.PONE.0133852
Ibrahim Lutfi Shuaib, Syed Ejaz Shamim, Lee Boon Nang, Nor Asiah Muhamad, Clinical determinants of fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)iodine whole body scans after (131)iodine therapy. The Malaysian journal of medical sciences. ,vol. 21, pp. 38- 46 ,(2014)
Burkhard Riemann, Uwe Mäder, Christoph Reiners, Frederik A. Verburg, Alexis Vrachimis, Endogenous TSH levels at the time of 131 I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 43, pp. 224- 231 ,(2016) , 10.1007/S00259-015-3223-2
Mira S. T. Torres, Luis Ramirez, Peter H. Simkin, Lewis E. Braverman, Charles H. Emerson, Effect of Various Doses of Recombinant Human Thyrotropin on the Thyroid Radioactive Iodine Uptake and Serum Levels of Thyroid Hormones and Thyroglobulin in Normal Subjects The Journal of Clinical Endocrinology and Metabolism. ,vol. 86, pp. 1660- 1664 ,(2001) , 10.1210/JCEM.86.4.7405
R. F. Gagel, H. Goepfert, D. L. Callender, CHANGING CONCEPTS IN THE PATHOGENESIS AND MANAGEMENT OF THYROID CARCINOMA CA: A Cancer Journal for Clinicians. ,vol. 46, pp. 261- 283 ,(1996) , 10.3322/CANJCLIN.46.5.261
Steven Orlov, Farnaz Salari, Lawrence Kashat, Jeremy L. Freeman, Allan Vescan, Ian J. Witterick, Paul G. Walfish, Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer Endocrine. ,vol. 50, pp. 130- 137 ,(2015) , 10.1007/S12020-015-0575-0
Richard J. Robbins, Albert Driedger, James Magner, , Recombinant Human Thyrotropin-Assisted Radioiodine Therapy for Patients with Metastatic Thyroid Cancer Who Could Not Elevate Endogenous Thyrotropin or Be Withdrawn from Thyroxine Thyroid. ,vol. 16, pp. 1121- 1130 ,(2006) , 10.1089/THY.2006.16.1121
Carole Spencer, Shireen Fatemi, Thyroglobulin antibody (TgAb) methods – Strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer Best Practice & Research Clinical Endocrinology & Metabolism. ,vol. 27, pp. 701- 712 ,(2013) , 10.1016/J.BEEM.2013.07.003
Luca Giovanella, Giorgio Treglia, Ramin Sadeghi, Pierpaolo Trimboli, Luca Ceriani, Frederik A. Verburg, Unstimulated highly sensitive thyroglobulin in follow-up of differentiated thyroid cancer patients: a meta-analysis. The Journal of Clinical Endocrinology and Metabolism. ,vol. 99, pp. 440- 447 ,(2014) , 10.1210/JC.2013-3156